reports
Dexcom and ŌURA Announce Strategic Partnership
SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in glucose biosensing, and , maker of the world’s leading smart ring, announced today a strategic partnership to help millions of people improve their metabolic health through the integration of Dexcom glucose data with vital sign, sleep, stress, heart health and activity data from Oura Ring. Combining Dexcom glucose data with the biometrics collected by Oura Ring will provide users of both products with a more complete picture of overall health. Dexcom is also making a $75 million strategic investment in ŌURA Serie...
Dexcom Helps People With Diabetes Take the First Step to Discover What...
SAN DIEGO--(BUSINESS WIRE)-- This World Diabetes Day, (NASDAQ: DXCM), the global leader in glucose biosensing technology, is encouraging people with diabetes globally to take the first step to discover what they’re made of. This comes as global data1 shows nearly 70% of people with diabetes say they didn’t know where to begin their health journey when they were first diagnosed, and nearly half said diabetes has limited their ability to pursue a passion or interest. This press release features multimedia. View the full release here: Dexcom is teaming up with its thousands of global brand advo...
Dexcom Reports Third Quarter 2024 Financial Results
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights: Revenue grew 2% year-over-year to $994.2 million on a reported basis and 3% year-over-year on an organic1 basis. U.S. revenue declined 2% and international revenue grew 12% on a reported basis and 16% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $152.0 million or 15.3% of revenue, a decrease of 580 basis points compared to the third quarter of 2023. Non-GAAP operating income* of $21...
Dexcom, Beyond Type 2 and Retta Establish National Glucose Awareness W...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in partnership with the nonprofit , are teaming up with author, producer and actress Retta to establish National Glucose Awareness Week from Sept. 23-29, 2024. will help close the glucose knowledge gap and encourage people to take action to own their glucose health. This press release features multimedia. View the full release here: Actress Retta teams up with Dexcom and Beyond Type 2 to establish National Glucose Awareness Week. (Photo: Business Wire) Understand...
Dexcom Brings Mentorship to Centerfield, Welcomes New, Star Athletes t...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of , the company’s groundbreaking NIL (name, image, likeness) program exclusively for college athletes with diabetes. This press release features multimedia. View the full release here: The Dexcom U 2024 roster consists of 20 athletes who all use Dexcom CGM to monitor their glucose levels and manage their diabetes (Graphic: Dexcom) Heralded by Ad Age as a after its inaugural season in 2022, the 2024 Dexcom U s...
Dexcom CGM Worn in Outer Space as Part of First-of-its-Kind Polaris Da...
SAN DIEGO--(BUSINESS WIRE)-- (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being worn by astronauts in space as part of the Polaris Dawn mission, which launched this morning and aims to better understand the effects of spaceflight on human health. While in orbit, the Polaris Dawn crew will conduct scientific research designed to advance both human health on Earth and our understanding of human health during long-duration spaceflights. Given that one in ten1 peo...
Dexcom to Showcase Transformational Impact of Dexcom CGM Technology at...
EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will spotlight the significant benefits of its innovative CGM technology at an upcoming symposium during the European Association for the Study of Diabetes (EASD) Conference on Monday, 9th September, 1300 – 1430 CEST. The symposium will feature expert panellists from endocrinology Prof. Michael Joubert MD PhD, France, primary care, Prof. Samuel Seidu MD, FRCP (EDIN), FRCGP, UK, Therapeutic Education, Dr. oec. troph. Astrid Tombek, German...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, and Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4th. The live presentation is scheduled to begin at approximately 11:00 AM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empow...
Stelo by Dexcom, the First Over-the-Counter Glucose Biosensor in the U...
SAN DIEGO--(BUSINESS WIRE)-- , Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter glucose biosensor in the U.S., is now available for purchase without a prescription4 at . This press release features multimedia. View the full release here: Stelo is designed to help people with Type 2 diabetes not using insulin and those with prediabetes. (Photo: Dexcom) Stelo is a small biosensor worn on the back of the upper arm that leverages Dexcom’s most accurate glucose sensing technology.5 It i...
La RAMQ élargit sa couverture provinciale pour inclure le Dexcom G7, o...
BURNABY, Colombie-Britannique--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ : DXCM), un chef de file mondial de la surveillance continue du glucose en temps réel (SCGtr) pour les personnes atteintes de diabète, a annoncé aujourd'hui que sa dernière innovation, le système de surveillance continue du glucose (SCG) Dexcom G7, sera ajoutée au régime public d'assurance médicaments de la Régie de l'assurance maladie du Québec (RAMQ). Les Québécois atteints de diabète de type 1 qui répondent aux critères d'admissibilité pourront désormais bénéficier d'une couverture pour le Dexcom G7*. Ce communiqué de pr...
RAMQ Expands Provincial Coverage to Include Dexcom G7, Bringing the Ne...
BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, announced today that its latest innovation, the Dexcom G7 Continuous Glucose Monitoring (CGM) System, will be added to the Régie de l'assurance maladie du Québec (RAMQ) Public Prescription Drug Insurance Plan. Québec residents living with type 1 diabetes who meet the eligibility criteria will now be able to receive coverage for Dexcom G7.* This press release features multimedia. View the full release here: Québec residents ages ...
Dexcom Reports Second Quarter 2024 Financial Results, Updates Guidance...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights: Revenue grew 15% year-over-year to $1.004 billion on a reported basis and 16% year-over-year on an organic1 basis. U.S. revenue grew 19% and international revenue grew 7% on a reported basis and 10% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $158.0 million or 15.7% of revenue, an increase of 100 basis points compared to the second quarter of 2023. Non-GAAP operating in...
Dexcom Schedules Second Quarter 2024 Earnings Release and Conference C...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that it plans to release its second quarter 2024 financial results after market close on Thursday, July 25, 2024. Management will hold a conference call to review the company's second quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at and will be archived there for future reference. To listen to the conference call, please dial (877) 344-3040 (US/Canada) or (646) 475-164...
Dexcom Inc: 1 director
A director at Dexcom Inc sold 6,000 shares at 117.005USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Dexcom Expands AID Partnership Into The Netherlands
EDINBURGH, Scotland--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced that people living with Type 1 diabetes in the Netherlands will be able to use a new tubeless Hybrid Closed Loop system (HCL) the Omnipod® 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), for an easier1-3 diabetes management experience. In the Netherlands, 100,000 people have type 1 diabetes, with an estimated 10,000 children affected*, making it the most common autoimmune disease among children after asthma 4....
Dexcom Showcases Extensive Clinical Data at ADA 2024 Demonstrating the...
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, will showcase its expanding focus on Dexcom CGM use among people with Type 2 diabetes, the launch of the Omnipod 5 Automated Insulin Delivery System with Dexcom G7 and its relentless commitment to innovation at the 84th Scientific Sessions of the American Diabetes Association conference held June 21–24, 2024, in Orlando. Dexcom: The CGM brand for people with Type 2 diabetes, prediabetes and those using GLP-1s This year at ADA, Dexcom is presenting more ...
Dexcom G7 Now Connects Directly to Apple Watch in the U.S.
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects directly to Apple Watch* in the United States. Dexcom G7 is the first and only CGM available with , offering users the freedom and convenience of real-time glucose readings on their wrist even when their iPhone isn’t with them.† This press release features multimedia. View the full release here: Diabetes management goes hands-free as Dexcom G7 now connects directly to Apple ...
Dexcom Wins Access to Dexcom One for 100,000 People Living With Type 2...
EDINBURGH, Scotland--(BUSINESS WIRE)-- (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating Type 2 diabetes (T2D) with basal insulin injections. The company, which pioneered CGM technology 25 years ago, has secured access to its Dexcom ONE sensor for around 100,000 T2D users in France. The reimbursement guidance offers people aged over two years who are on non-intensified insulin therapy (less than 3 injections a day) and whose glycaemic control is insufficien...
Nova Scotia Now Providing Coverage for Dexcom Continuous Glucose Monit...
BURNABY, British Columbia--(BUSINESS WIRE)-- Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, today announced that residents of Nova Scotia living with either type 1 or type 2 diabetes who use intensive insulin and meet eligibility criteria now have coverage for Dexcom G6 and Dexcom G7 continuous glucose monitoring (CGM) systems. This press release features multimedia. View the full release here: Eligible residents living with diabetes in Nova Scotia with type 1 diabetes or type 2 diabetes using insulin may now be eligib...
Dexcom Announces Upcoming Conference Presentation
SAN DIEGO--(BUSINESS WIRE)-- (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5th. The live presentation is scheduled to begin at approximately 4:20 PM EST and will be concurrently webcast. Links to the webcast will be available on the Dexcom Investor Relations website at and will be archived there for future reference. About DexCom, Inc. DexCom, Inc. empowers people to take real-time control of health through innova...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.